Prescribed Drugs Provider Manual - Iowa Department of Human ...
Prescribed Drugs Provider Manual - Iowa Department of Human ...
Prescribed Drugs Provider Manual - Iowa Department of Human ...
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>Iowa</strong><strong>Department</strong><strong>of</strong> <strong>Human</strong>Services<strong>Provider</strong> and Chapter<strong>Prescribed</strong> <strong>Drugs</strong>Page3DateAugust 1, 2013Page47. Linezolid (Zyvox ® ) ............................................................................. 4948. Mifepristone (Korlym ® )....................................................................... 5049. Modified Formulations ........................................................................ 5050. Muscle Relaxants ............................................................................... 5151. Narcotic Agonist-Antagonist Nasal Sprays .............................................. 5152. Nebivolol (Bystolic ® ) .......................................................................... 5253. Nicotine Replacement Products ............................................................ 5254. Nonparenteral Vasopressin Derivatives <strong>of</strong> Posterior Pituitary HormoneProducts ........................................................................................... 5355. Nonpreferred <strong>Drugs</strong> ........................................................................... 5456. Nonsteroidal Anti-Inflammatory <strong>Drugs</strong> .................................................. 5457. Omalizumab (Xolair ® ) ........................................................................ 5558. Oxycodone ER/CR (OxyContin ® ) .......................................................... 5659. Palivizumab (Synagis ® ) ...................................................................... 5660. Proton Pump Inhibitors ....................................................................... 5861. Pulmonary Arterial Hypertension Agents ................................................ 5962. Quantity Limit Override ...................................................................... 60a. Initial 15-Day Limit ..................................................................... 60b. Monthly Limits ............................................................................ 6063. R<strong>of</strong>lumilast (Daliresp) ...................................................................... 8164. Sedative/Hypnotics-Non-Benzodiazepine ............................................... 8265. Selected Brand-Name <strong>Drugs</strong> ................................................................ 8266. Serotonin 5-HT1 Receptor Agonists ...................................................... 8367. Short-Acting Narcotics ........................................................................ 8468. Smoking Cessation Therapy-Oral ......................................................... 8469. Sodium Oxybate (Xyrem ® ).................................................................. 8570. Thrombopoietin Receptor Agonists ....................................................... 8571. Topical Retinoids ............................................................................... 8672. Vemurafenib (Zelboraf).................................................................... 8773. Vilazodone (Viibryd ) ......................................................................... 8774. Vitamins, Minerals and Multiple Vitamins ............................................... 8875. Vusion Ointment ............................................................................. 88D. BASIS OF PAYMENT FOR DRUGS AND SUPPLIES ............................................ 891. Reimbursement Effective February 1, 2013 ........................................... 90a. Generic and Nonprescription <strong>Drugs</strong> ............................................... 90b. Brand-Name <strong>Drugs</strong> ..................................................................... 902. <strong>Drugs</strong> Subject to Federal Upper Limit (FUL) ........................................... 90a. FUL Development ....................................................................... 90b. Reimbursement for FUL <strong>Drugs</strong> ...................................................... 913. Reimbursement for Unit-Dose Packaging ............................................... 914. Reimbursement for Vaccinations .......................................................... 92